Showing results (131-140 of 342) with videos related to
Sort By:
Pageof 35
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2016
Reprint of: Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United StatesJane Apperley, Dietger Niederwieser, Xiao-jun Huang, et al.British Journal of Haematology|March 4, 2006
Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher diseaseItai Magal, Ehud Lebel, Gheona Altarescu, et al.Journal of Clinical Medicine|December 23, 2023
Cancer Risk in Patients with Gaucher Disease Using Real-World DataShoshana Revel-Vilk, Ari Zimran, Majdolen Istaiti, et al.British Journal of Haematology|March 16, 2011
Platelet adhesion defect in type I Gaucher Disease is associated with a risk of mucosal bleedingGalia Spectre, Batia Roth, Galia Ronen, et al.Blood Cells, Molecules & Diseases|November 15, 2016
Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trialsAri Zimran, Deborah Elstein, Derlis E Gonzalez, et al.Blood Cells, Molecules & Diseases|September 16, 2003
The 1604A (R496H) mutation in Gaucher disease: genotype/phenotype correlationAriel Brautbar, Deborah Elstein, Aya Abrahamov, et al.Blood Cells, Molecules & Diseases|December 26, 2012
Phenotype in patients with Gaucher disease and Parkinson diseaseEli Ben Chetrit, Roy N Alcalay, Bettina Steiner-Birmanns, et al.Blood Cells, Molecules & Diseases|December 3, 2014
Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher diseaseAri Zimran, Derlis Emilio Gonzalez-Rodriguez, Aya Abrahamov, et al.Mhealth|November 10, 2025
MyGauchTM: a patient-centered digital health app for Gaucher diseaseMajdolen Istaiti, Elena Shulman, Tama Dinur, et al.Blood Cells, Molecules & Diseases|November 4, 2011
Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from JerusalemDeborah Elstein, Gheona Altarescu, Hannah Maayan, et al.Pageof 35